hoe-777 and Dermatitis--Allergic-Contact

We cannot as yet fully answer the question of the safety of the new corticosteroids. Budesonide is frequently found to be an allergen now that it is being marketed, and it can certainly serve as a primary sensitizer. For the other new corticosteroids, too, we already had numerous positive tests even before they were marketed. This must be considered cross-sensitivity. We will have to wait to see whether or not they are primary sensitizers. For the pharmaceutical industry, there is one more challenge in the development of new corticosteroids: In addition to finding more effective corticosteroids with the fewest "classic" side effects, the industry will also have to identify the least sensitizing molecules.

Topics: Administration, Topical; Adrenal Cortex Hormones; Allergens; Androstadienes; Animals; Anti-Inflammatory Agents; Budesonide; Dermatitis, Allergic Contact; Drug Eruptions; Fluticasone; Glucocorticoids; Humans; Mometasone Furoate; Prednisolone; Pregnadienediols; Pregnenediones

Corticosteroids are among the most commonly used topical drugs. Contact allergy to these exists, but can be easily missed. Corticosteroid screening markers have been included in the baseline series with the aim of detecting most of the sensitized patients.. To assess the prevalence of contact allergy to topical corticosteroids in Spain and examine the usefulness of corticosteroid markers to detect contact allergy to corticosteroids.. In total, 3699 patients referred to 20 dermatology departments across Spain for patch testing with the baseline series, including budesonide and tixocortol pivalate, were also tested with six supplementary corticosteroids (methylprednisolone aceponate, mometasone furoate, prednicarbate, clobetasol propionate, betamethasone 17-valerate, and betamethasone 17,21-dipropionate). Additionally, 2547 (68.8%) patients were tested with hydrocortisone 17-butyrate.. Fifty-four patients showed positive reactions to at least one of all tested corticosteroids (1.46%). Thirty-nine (1.05%) reacted to at least one of the additionally tested corticosteroids; among these, 24 of 39 (61.5%) did not react to any of the corticosteroid allergy screening markers tested.. More than half of the patients who were allergic to the additionally tested corticosteroids were not detected with the corticosteroid allergy markers. An update of the corticosteroid allergy screening markers is encouraged, with consideration of group 3 corticosteroids.

Topics: Administration, Cutaneous; Adult; Betamethasone; Betamethasone Valerate; Clobetasol; Dermatitis, Allergic Contact; Dermatologic Agents; Female; Humans; Hydrocortisone; Male; Methylprednisolone; Mometasone Furoate; Patch Tests; Predictive Value of Tests; Prednisolone; Prevalence; Prospective Studies; Spain

Topics: Adult; Budesonide; Chronic Disease; Cross Reactions; Dermatitis, Allergic Contact; Female; Glucocorticoids; Hand Dermatoses; Humans; Hydrocortisone; Patch Tests; Prednisolone

Topics: Allergens; Cross Reactions; Dermatitis, Allergic Contact; Diagnosis, Differential; Facial Dermatoses; Female; Humans; Lupus Erythematosus, Cutaneous; Middle Aged; Patch Tests; Prednisolone

Topics: Administration, Topical; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Budesonide; Child; Child, Preschool; Dermatitis, Allergic Contact; Female; Glucocorticoids; Humans; Male; Middle Aged; Patch Tests; Prednisolone

Topics: Administration, Topical; Aged; Anti-Inflammatory Agents; Dermatitis, Allergic Contact; Edema; Erythema; Genitalia, Male; Glucocorticoids; Humans; Male; Patch Tests; Prednisolone

Topics: Administration, Topical; Anti-Inflammatory Agents; Dermatitis, Allergic Contact; Glucocorticoids; Humans; Male; Middle Aged; Patch Tests; Prednisolone